Isotretinoin
- Generic Name
- Isotretinoin
- Brand Names
- Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 4759-48-2
- Unique Ingredient Identifier
- EH28UP18IF
- Background
Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne. It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-cont...
- Indication
Isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.
- Associated Conditions
- Acne conglobata, Neuroblastoma (NB), Rosacea, Sezary Syndrome, Early Mycosis Fungoides (MF), Refractory Acne vulgaris, Severe Recalcitrant nodular acne
- Associated Therapies
- -
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1449
- Registration Number
- NCT00026312
- Locations
- 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸UCSF Medical Center-Mission Bay, San Francisco, California, United States
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00040872
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 175
- Registration Number
- NCT00030719
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Ghent, Belgium
🇳🇴Rikshospitalet University Hospital, Oslo, Norway
🇬🇧Birmingham Children's Hospital, Birmingham, England, United Kingdom
Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 150
- Registration Number
- NCT00001073
- Locations
- 🇺🇸
Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States
🇺🇸UW School of Medicine - CHRMC, Seattle, Washington, United States
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 98
- Registration Number
- NCT00000764
- Locations
- 🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
- Conditions
- First Posted Date
- 2001-04-11
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT00014729
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.